ArticleNaunyn-Schmiedeberg's archives of pharmacology1996
Release of noradrenaline from isolated rat tail artery induced by bafilomycin A1.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The macrolide antibiotic bafilomycin A1, a selective inhibitor of the vesicular H(+)-transporting ATPase, increased irreversibly the overflow of 3,4-dihydroxyphenylethylene glycol from isolated segments of the rat tail artery. Maximum increase in the overflow was produced by exposing the tissues to 0.5 mumol/l bafilomycin A1. Unless the Na(+)-dependent neuronal amine carrier (uptake1) was inhibited, overflow of noradrenaline was below the detection limit. The bafilomycin A1-induced increase in overflow of noradrenaline from tissues with inhibited uptake1 was accompanied by a significant decrease in the (noradrenaline overflow:glycol overflow) ratio. Unlike reserpine and tetrabenazine, the antibiotic did not alter the (noradrenaline overflow:glycol overflow) ratio in arteries incubated in Ca(2+)-free, 120 mmol/l K+ medium. Bafilomycin A1 increased overflow of noradrenaline and normetanephrine from tissues with inhibited monoamine oxidase. Inhibitors of extraneuronal catecholamine transport (uptake2), corticosterone, 3-O-methylisoprenaline and 1,1'-diethyl-2,2'-cyanine, suppressed overflow of normetanephrine while increasing that of noradrenaline. Further increase in overflow of noradrenaline was produced by concomitant inhibition of uptake1. A similar effect was observed in tissues previously exposed to phenoxybenzamine. After exposure to bafilomycin A1, tyramine and (+) amphetamine (10 mumol/l) were equally effective in increasing overflow of noradrenaline from tissues with inhibited monoamine oxidase into corticosterone-containing medium. Bafilomycin A1 promotes leakage of noradrenaline from storage vesicles without affecting its conversion to 3,4-dihydroxyphenylethylene glycol. When uptake1 is inhibited, axoplasmic noradrenaline can be translocated effectively across the axonal membrane by the 'diffusional efflux'. When uptake1 is inhibited, spontaneous quantal release contributes significantly to overflow of noradrenaline into normal media. The 'diffusional efflux' of noradrenaline is unaffected by inhibitors of uptake2. Even at highly elevated concentrations of axoplasmic noradrenaline, the uptake1-mediated influx of noradrenaline exceeds the uptake1-mediated efflux. Enhancement of noradrenaline overflow from tissues with inhibited monoamine oxidase by indirectly acting sympathomimetic amines depends primarily on their ability to induce leakage of the transmitter from storage vesicles rather than its translocation across the axonal membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.